RedHill Biopharma’s RHB-204 Granted FDA Fast Track Designation for NTM Disease
TEL AVIV, Israel and RALEIGH, NC, Jan. 6, 2021 /PRNewswire/ — RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or “the Company”), a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for…
Comments Off on RedHill Biopharma’s RHB-204 Granted FDA Fast Track Designation for NTM Disease